Objectives. We examined the efficacy, safety and patient satisfaction of intra-articular hyaluronic acid (HA) in patients with osteoarthritis of the knee.
Osteoarthritis (OA) of the knee is very common and toms in patients with OA of the knee [3] [4] [5] . This type very important. Population surveys have shown that of action is characteristic of a group of compounds radiographically determined OA of the knee is present called 'slow acting symptomatic drug for osteoarthritis' in between 15 and 30% of subjects aged over 45 yr, and
[6 ] to distinguish them from NSAIDs. thereafter increases steadily with age [1, 2] . Current HyalganA, used in this study, is a highly purified, treatment is usually disappointing and most rheumaconcentrated (10 mg/ml ), viscous solution of natural tologists do not follow-up patients once the diag-HA with a molecular weight in the range of 500-nosis is made. Non-steroidal anti-inflammatory drugs 730 kDa, extracted from rooster combs. In studies (NSAIDs) have been the mainstay of drug treatment in reported to date [3] [4] [5] , HyalganA has been very well knee OA, as in other types of arthritis, but have obvious tolerated with no significant side-effects apart from the limitations. The elderly are most at risk from serious possibility of transient localized pain after the injection. adverse effects of these drugs, particularly peptic ulcerWhile most studies have found HyalganA to be effective, ation, bleeding or perforation. Intra-articular steroids
Henderson et al. [7] failed to show a difference in a are used in OA, but their long-term efficacy is not well placebo-controlled study. This 6 month study of 91 established.
patients had a high percentage of withdrawals (38%) Intra-articular sodium hyaluronate (hyaluronic acid; and local adverse effects (pain and/or swelling: 47% in HA) offers the prospect of another approach to the the HA group and 22% with placebo). This may have treatment of OA. Studies have shown that a course of resulted in an insufficient power to detect a difference five injections of HA provides prolonged relief of sympin the completed patients. The question, therefore, regarding the efficacy of HyalganA over placebo remains Clinical assessments were made at baseline, at weekly Patients visits over 4 weeks, 1 week after the final injection (week One hundred fully ambulant patients attending a hos-5), and at months 2, 4 and 6. During the treatment pital out-patient clinic with a diagnosis of OA of one phase, the clinical assessments were carried out before or both of the knees according to the ARA criteria [8] each injection. were included. All patients had radiographic changes of
The primary efficacy criteria in the study were knee OA equal to Kellgren and Lawrence grade II or III [9] pain on walking as recorded by the patient on a 100 mm on an X-ray taken within the 6 months prior to study visual analogue scale ( VAS ) [10] and knee function as entry. All patients had consistent pain for the 3 months assessed by the Lequesne Functional Index [11] . prior to recruitment and moderate or severe pain on Secondary efficacy parameters were knee pain at rest walking at both the initial screening visit and at the scored on a 100 mm VAS, joint tenderness and swelling baseline visit.
assessed using a four-point nominal scale (none, mild, Exclusion criteria included X-rays showing grade IV moderate or severe), morning stiffness and inactivity change on the Kellgren and Lawrence scale, serious stiffness in minutes, patient's global impression of effifunctional impairment at the knee, associated OA of the cacy recorded on a four-point scale (excellent, fair, poor hip of sufficient severity to interfere with assessment of or useless), patient satisfaction with the treatment evaluthe knee or OA of any other joint which might have ated by a Satisfaction Index which assessed overall hindered assessment of the knee, psoriasis, radiographic satisfaction, satisfaction based on perceived efficacy or evidence of sacroiliitis or any other joint disease other adverse reactions on separate 100 mm VAS and satisfacthan OA, known or suspected joint infection, poor tion, pain relief, anti-inflammatory effect, therapeutic general health or other conditions which would prevent outcome and therapeutic preferences on separate fiveregular hospital attendance, skin conditions overlying point nominal scales [12, 13] . the joint which might make injection dangerous, painful
The occurrence of adverse events was assessed at all knee conditions other than OA like Sudek's atrophy visits. Throughout the study, patients were permitted to or Paget's disease, severe intercurrent hepatic or renal continue with existing analgesic or anti-inflammatory disease or major general medical conditions, and use of therapy as considered appropriate by the referring physian intra-articular steroid or radiocolloid within the 3 cian. A record of all treatments was maintained at months before the start of treatment.
each visit. The study was conducted in the Department of Rheumatology at St Bartholomew's Hospital, London,
Statistical methods after approval of the ethics committee. Written informed
The pain on walking efficacy parameter was used to consent was obtained from all patients.
determine the number of patients to be recruited into the study, i.e. the sample size. The standard deviation Study design calculated from changes in joint pain score on walking, This was a randomized, placebo-controlled, 'blindas recorded on a 100 mm VAS, was expected to be observer', parallel group study with a 6 month follow-~2 4 mm [14] . up period, comparing the efficacy of five weekly intraOn this basis, a sample size of 50 patients for each articular injections of HA (20 mg/2 ml, HyalganA, group would give a power of around 90% for the Fidia, Abano Terme, Italy) with five weekly intradetection of a mean treatment change of 15.4 mm in the articular injections of placebo (2 ml saline) in the treatpain on walking score, using a two-tailed test at the 5% ment of knee OA. HA and placebo were both formulated significance level. in a buffered aqueous solution.
The principal analysis for the primary efficacy criteria Because of the differences in viscosity between the was the analysis of covariance (ANCOVA) using the drug and placebo, it was necessary to use a blind corresponding baseline (week 0) assessment as the observer. The intra-articular injections were adminiscovariate, performed at week 5 and month 6 using the tered by a single physician (SD) who did not discuss data of all randomized patients who had the observathe treatment with either patient or observer; the efficacy tions at 6 months. Where appropriate, additional anaassessments were carried out by an experienced rheumalyses were carried out for these parameters at months 2 tology nurse who was not aware of the treatment given. and 4. If there was evidence of statistically significant differences in the two groups at baseline (P < 0.10) for Study procedure important prognostic factors, adjustment for these factors was made in the statistical analysis. Following initial screening, patients who fulfilled the entry criteria were admitted to the trial. The patients For the continuous secondary parameters, ANCOVA was also carried out, whereas categorical data were were re-examined 2 weeks later to verify the entry criteria, including pain severity. At this visit (baseline analysed by the x2 test. All statistical tests for efficacy parameters were performed using a two-tailed test, with visit), patients were randomly assigned to receive either intra-articular HA or placebo in the affected knee joint.
a significance level of a = 0.05. All efficacy results are presented for patients who Patients received five weekly injections of HA or placebo T completed the 6 months follow-up. For the principal groups which favoured HA but were not significant. There were no differences between the groups in the efficacy criteria (pain on walking), a 'Last Observation Carried Forward' (LOCF ) analysis on all 100 randomnominal scores for joint tenderness, morning stiffness or inactivity stiffness at any time point. However, at week ized patients was performed as an intention-to-treat outcome.
5, 42.5% of the HA-treated patients compared with 29.3% of the placebo patients reported no morning The Statistical Analysis Systems (SAS ) software was used in the statistical analyses (SAS Institute, Cary, stiffness (P = 0.214) and, at month 6, 35.9% of the patients in the HA group and 22.5% in the placebo NC, USA).
group reported no inactivity stiffness (P = 0.190).
In the patient's global impression, a significant differResults ence was found in favour of HA compared to placebo at month 6 (P = 0.012). At this time, 75% of the A total of 100 patients, 33 males and 67 females, were recruited into the study and were assigned to one of the HA-treated patients rated the treatment as either excellent or fair compared with 47.5% of the placebo-treated two treatment groups, 50 patients in each group. Baseline characteristics of the two groups ( Table 1) were patients.
In overall patient satisfaction, using the VAS, there comparable except for sex distribution (P = 0.056).
Ninety-four patients completed the 5 week treatment was no difference at week 5 (P = 0.276), but, at month 6, there was a significant preference for HA (P = 0.006). course and 81 patients completed the 6 month followup. Of the 19 patients who withdrew from the study, Perceived treatment efficacy using VAS favoured HA, but was not significant. Using a five-point nominal scale, six withdrew during the treatment period (week 0-4): four patients in the HA group, all for reasons unrelated the only significant difference was in perceived efficacy at month 6 only in favour of HA (P = 0.017). There to the treatment, and two patients in the placebo group, both for lack of efficacy. During the follow-up period, were no differences in perceived adverse effects between the groups. a further 13 patients withdrew from the study. Six withdrew from the HA group, two due to the onset of In anti-inflammatory efficacy, using VAS, the difference significantly favoured HA only at month 6 non-drug-related side-effects (removal of a calf ulcer in one, flare-up at month 4 in the other), two due to lack (P = 0.011). In perceived disease progression, the response was significant in favour of HA at week 5 of efficacy and two who were lost to follow-up. Seven were withdrawn from the placebo group, six due to lack (P = 0.006), but not at month 6 (P = 0.078). In patient of efficacy and one for a non-drug-related side-event (a flare-up at month 4).
T 2. Pain on walking by VAS (completed patients)
Primary efficacy criteria
Pain on walking. The results are shown in Table 2 on all randomized patients, using the LOCF, also showed a significant result favouring HA (P = 0.0010). Lequesne Functional Index. The results are shown in Table 3 and Fig. 2 . At week 5, a significant difference in almost to month 4 (P = 0.0528), but the difference was not significant at month 6. acceptability, there was a significant benefit in favour of HA at month 6 (P = 0.025). For the other items of the questionnaire (perceived pain relief, duration of pain relief and patients' preferred treatment), although there were consistent trends in favour of HA at week 5 and month 6, these did not reach significance. At baseline, the presence of an effusion was observed in 35 patients (14 placebo and 21 HA). Of the 14 patients in the placebo group with an effusion at baseline, nine (64.28%) did not have effusion at week 5; in the HA group, the number of patients without effusion at this time was 14 out of 19 (73.7%). At month 6, the percentages of patients with an effusion at baseline for whom the effusion disappeared were 58.3% (7/12) in the placebo group and 75.0% (12/16) in the HA group.
Concomitant medications
The consumption of anti-inflammatory drugs throughout the study was low. The number of patients who took NSAIDs was very similar in both groups during during the 6 month follow-up (five HA, six placebo). Only one patient in the HA group took analgesics during the treatment period.
group (one during the treatment, one during and after the treatment, and three during the follow-up) reported Adverse events adverse events which were not associated with local reactions in the knee joint area. Of these, one in the HA A total of 31 patients (14 from the placebo group and 17 from the HA group) reported adverse events during group was felt to be severe and possibly treatment related. The patient developed a cutaneous vasculitis the study. The majority reported local reactions at the injection site during the treatment phase with no differprogressively spreading from both legs to the abdomen and arms. The event occurred within the first week of ences between placebo or active drug. Flare at the knee joint was recorded in seven patients in each group. treatment and progressed during the course of the study. The patient did not, however, interrupt the study. One Effusion was present in only one patient in the HA group compared with three patients in the placebo group.
other adverse event, which occurred in the HA group 8 days after the last injection, was considered severe and Eleven patients in the HA group (five during the treatment, one during and after the treatment, and five possibly drug related. This was a skin reaction characterized by peeling of the skin on the hands and toes, and during the follow-up) and five patients in the placebo erythema which improved during the course of the reported after injections of HA, but in this study they were equally common in the placebo group. Cutaneous study. At the 6 month follow-up, the reaction appeared milder than at its onset.
vasculitis has not been reported elsewhere in patients receiving HA, even though the product has been availIn the placebo group, there were no adverse events considered to be related to treatment. One patient in able in 20 countries for several years and widely used. In these circumstances, its relationship to the treatment the placebo group experienced a myocardial infarction during the second week of the study. must be regarded as unproven. The low incidence of side-effects and the safety of HA will make it particularly suitable for the treatment of OA in elderly patients who Discussion cannot tolerate NSAIDs or for whom they are contraindicated. This study clearly demonstrates that a course of five weekly injections of HA (HyalganA) is effective, superior
With its prolonged pain-relieving potential and avoiding the possible problems of anti-inflammatory to placebo, and acceptable to patients with OA of the knee. It confirms many other studies which have demondrugs in the stomach, HyalganA has obvious potential in the management of OA of the knee in the elderly as strated similar effects. Of particular relevance is a recent 6 month, US multicentre study [4] comparing a course well as in patients whose disease cannot easily be controlled in simpler ways. It is likely to be useful for other of five weekly intra-articular injections of HA with five weekly intra-articular placebo injections and continuous joints and its effects on the course and outcome of the disease remain to be explored. A novel approach to the oral naproxen. HA was superior to placebo and at least as effective as oral naproxen. There were significantly treatment of such a common disease as OA is particularly welcome and is a reflection of the increasing interest more premature terminations due to gastrointestinal side-effects in the naproxen group. Our study confirms in the disease process and in possible ways of modifying it. these findings with respect to placebo, but, unlike the US study, we observed a gradual decline in patient efficacy in both the HA and placebo patients which may ate in OA. The mode of action of injected HA is unclear. 
